Product Description
a long-acting injectable GLP-1 analogue for short bowel syndrome
Mechanisms of Action: GLP-1 Agonist
Novel Mechanism: No
Modality: Fusion Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: 9 Meters Biopharma
Company Location: RALEIGH NC 27615
Company CEO: John Temperato
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Short Bowel Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NMSBS01-002 | P2 |
Terminated |
Short Bowel Syndrome |
2022-08-05 |
24% |
| NMSBS01-001 | P2 |
Unknown status |
Short Bowel Syndrome |
2020-12-11 |
24% |